The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Members of the European Parliament, researchers, patient advocates, national experts, and representatives from the biotech ...